Related Experiment Video
Updated: Aug 25, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
[Secondary prophylaxis after myocardial infarction, bypass surgery and percutaneous coronary intervention]
Jan Eritsland1, Harald Arnesen
1Hjertemedisinsk avdeling, Hjerte-lunge-senteret, Ullevål universitetssykehus, 0407 Oslo. jeri@uus.no
Insights
Patients with atherosclerotic coronary artery disease need aggressive secondary prevention. Treatment includes lifestyle changes, statins, and antiplatelet or anticoagulant therapies to prevent thrombotic complications.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Context:
- Atherosclerotic coronary artery disease (CAD) affects patients post-myocardial infarction (MI) and those undergoing percutaneous coronary intervention (PCI) or coronary bypass surgery (CBS).
- These patients require intensive secondary prophylaxis to mitigate risks associated with thrombotic complications.
Purpose:
- To outline evidence-based secondary prevention strategies for patients with established atherosclerotic CAD.
- To guide treatment decisions regarding pharmacotherapy and lifestyle modifications for secondary prophylaxis.
Summary:
- Aggressive secondary prophylaxis is crucial, encompassing lifestyle modifications, statin therapy, and antiplatelet/anticoagulant treatments.
- Post-MI patients may benefit from anticoagulation and acetylsalicylic acid (aspirin). Post-revascularization, aspirin is primary, with clopidogrel as an alternative if aspirin is contraindicated.
- Dual antiplatelet therapy (aspirin and clopidogrel) is recommended for up to one year post-coronary stenting. Anticoagulation can be added if needed, with specific International Normalized Ratio (INR) targets.
- Beta-blockers and ACE inhibitors are recommended post-MI. n-3 polyunsaturated fatty acids may offer additional benefits.
Impact:
- Optimized secondary prevention strategies can significantly reduce recurrent cardiovascular events and improve outcomes in high-risk CAD patients.
- This guidance supports clinical decision-making for healthcare providers managing patients with CAD, promoting adherence to best practices.
- Effective management of thrombotic risk factors is essential for long-term patient well-being and reducing healthcare burden.
Abstract:
Patients who have sustained a myocardial infarction as well as patients treated with percutaneous coronary intervention or coronary bypass surgery have atherosclerotic coronary artery disease. They will need aggressive secondary prophylaxis, including modification of lifestyle risk factors. Most of these patients should be treated with statins. As clinical events often are manifestations of thrombotic complications, this patient group should be treated with platelet inhibition, anticoagulation, or both. After a myocardial infarction patients should be considered for anticoagulant treatment, for acetylsalicylic acid, or both. After coronary revascularisation acetylsalicylic acid should be considered primarily. If acetylsalicylic acid is contraindicated, clopidogrel is an alternative. After coronary stenting acetylsalicylic acid and clopidogrel should be prescribed combined, for up to one year afterwards. If indicated, anticoagulant treatment can be added to platelet inhibition. After bypass surgery, anticoagulation is equally effective as acetylsalicylic acid against graft occlusion and can be given alone if indicated. International Normalized Ratio can be aimed at 3.0 when anticoagulation is given alone, at 2.0-2.5 when combined with platelet inhibition. After a myocardial infarction patients should be given a beta-blocker if this is not strongly contraindicated and they also should be considered for ACE inhibitor treatment. These patients also seem to profit from a moderate supplement of n-3 polyunsaturated fatty acids.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management